MedTrace Logo

Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light

NCT05872854 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-02-09

No results posted yet for this study

Summary

The goal of this clinical trial is to assess the benefit of continuous treatment with synthetic hypericin ointment (HyBryte) and visible light in patients with mycosis fungoides for up to 12 months (54 weeks). Funding Source: FDA OOPD.

Conditions

Interventions

DRUG

Hypericin

HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment

OTHER

Visible Light

After application of HyBryte (0.25% hypericin ointment), participants will be placed in a light booth containing fluorescent light bulbs to activate the HyBryte.

Sponsors & Collaborators

  • Soligenix

    collaborator INDUSTRY

  • Ellen Kim, MD

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-21
Primary Completion
2025-12-22
Completion
2025-12-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05872854 on ClinicalTrials.gov